BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25614375)

  • 1. Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer.
    Monsó E; Montuenga LM; Sánchez de Cos J; Villena C;
    Arch Bronconeumol; 2015 Sep; 51(9):462-7. PubMed ID: 25614375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases.
    Bergman P; Brodin D; Lewensohn R; de Petris L
    Acta Oncol; 2013 Aug; 52(6):1189-94. PubMed ID: 23215828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
    Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P;
    J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
    Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
    Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors.
    Sánchez de Cos Escuín J; Abal Arca J; Melchor Íñiguez R; Miravet Sorribes L; Núñez Ares A; Hernández Hernández JR; García Arangüena L; Núñez Delgado M; Pavón Fernández MJ; Francisco Corral G; de Esteban Júlvez L; González Budiño MT; Abad Cavaco F; Ansótegui Barrera E; Andreo García F; Serra Mitjans M; Hernández Rodríguez H
    Lung Cancer; 2014 May; 84(2):182-9. PubMed ID: 24629637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
    Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
    Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small cell lung cancer staging: proposed revisions to the TNM system.
    Schneider BJ
    Cancer Imaging; 2008 Sep; 8(1):181-5. PubMed ID: 18824424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer.
    Rami-Porta R; Bolejack V; Giroux DJ; Chansky K; Crowley J; Asamura H; Goldstraw P;
    J Thorac Oncol; 2014 Nov; 9(11):1618-24. PubMed ID: 25436796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
    Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
    J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR
    J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
    Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
    Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.